For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Teijin: Pharma Sales Up 2.2%
November 22, 2010
- Astellas Sues Nycomed US to Protect Protopic Patents
November 22, 2010
- Sawai Proposes Business Integration to Kyorin
November 22, 2010
- Otsuka HD to Go Public in December
November 22, 2010
- TMX-67 to Be Launched in Japan after Spring 2011
November 22, 2010
- Takeda Accelerates Investment in Bioventures
November 22, 2010
- Takata to Comarket Ecbarl with Shionogi
November 22, 2010
- Asahi Kasei Pharma: Sales Remain Flat Despite Strong Sales of Recomodulin
November 22, 2010
- Janssen Voluntarily Recalls Anticancer Drug Velcade
November 22, 2010
- MTPC to Launch Nearly 10 New Products by FY2015
November 22, 2010
- JT: Pharma Business Driven by Torii
November 22, 2010
- Sales of Ethical Drugs Up 0.2% in September: Crecon Report
November 22, 2010
- Kaken to Increase Its No. of MRs to 800
November 22, 2010
- Yakult Honsha: Elplat Drives Pharma Business
November 22, 2010
- Eribulin Approved by FDA: Eisai
November 22, 2010
- Combined Sales of 23 Listed JPMA Member Companies Up 1.4%
November 22, 2010
- Sato to Launch Switch OTC Steroidal Agent
November 22, 2010
- GRU Criticizes Korosho for Not Discussing Range of OTC-like Drugs to Be Excluded from Insurance Coverage
November 22, 2010
- Kyorin: Sales Up 2.2% Driven by Kipres
November 22, 2010
- Price Settlement Rate 49.8% as of Sept. 30: CEO Kumakura of MEDIPAL
November 22, 2010
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…